ArticleAIDS (London, England)2019
Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics.
Article in AIDS (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Oral pre-exposure prophylaxis retention among men who have sex with men and transgender persons: Systematic review and meta-analysis.PloS one · 2025Pooled it
- Running with Scissors: a Systematic Review of Substance Use and the Pre-exposure Prophylaxis Care Continuum Among Sexual Minority Men.Current HIV/AIDS reports · 2022Pooled it
- Racial/Ethnic Disparity Among Persons Newly Diagnosed with HIV in New York State.AIDS and behavior · 2026Article
- High Retention and Adherence With Rapid Long-acting Injectable Preexposure Prophylaxis Implementation in an Urban Safety Net Clinic Population.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Individual & joint associations of sexual stigma and mental distress with PrEP uptake, adherence and persistence among US gay and bisexual men.Social science & medicine (1982) · 2024Article
- Understanding Typology of Preexposure Prophylaxis (PrEP) Persistence Trajectories Among Male PrEP Users in the United States.Open forum infectious diseases · 2024Article
- Unawareness of partner risk factors thwarts implementation of USPSTF recommendations for HIV pre-exposure prophylaxis in primary care.AIDS care · 2024Article
- PrEP Among Sub-Saharan African Diaspora Communities in Belgium - a Participatory Action Research Study.Journal of community health · 2024Article
- Cannabis Use Frequency is Associated with PrEP Cessation and Self-reported HIV Diagnosis.AIDS and behavior · 2023Article
- Motivational Enhancement Interventions to Increase Pre-Exposure Prophylaxis Use in Sexual Minority Men Who Use Stimulants: Protocol for a Pilot Sequential Multiple Assignment Randomized Trial.JMIR research protocols · 2023Article
- PrEP Persistence Support and Monitoring in Areas of High HIV Burden in the Midwestern United States.AIDS education and prevention : official publication of the International Society for AIDS Education · 2023Article
- Exploring the Association Between Gender Affirmation and PrEP use Among Transgender Women in New York City.AIDS and behavior · 2023Article
- Insights into barriers and facilitators in PrEP uptake and use among migrant men and transwomen who have sex with men in Belgium.BMC public health · 2023Article
- Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.JMIR public health and surveillance · 2023Article
- Providing gender-affirming care to transgender and gender-diverse individuals with and at risk for HIV.Topics in antiviral medicine · 2023Review
- Predictors of Human Immunodeficiency Virus Pre-Exposure Prophylaxis (PrEP) Uptake in a Sexual Health Clinic With Rapid PrEP Initiation.Open forum infectious diseases · 2023Article
- Pre-exposure prophylaxis in the era of emerging methods for men who have sex with men in the USA: the HIV Prevention Cycle of Care model.The lancet. HIV · 2023Review
- Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.Lancet regional health. Americas · 2023Article
- The Long-Acting Cabotegravir Tail as an Implementation Challenge: Planning for Safe Discontinuation.AIDS and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveDissemination of preexposure prophylaxis (PrEP) is a priority for reducing new HIV infections, especially among vulnerable populations. However, there are limited data available on PrEP discontinuation following initiation, an important component of the PrEP cascade.
designPatients receiving PrEP within the San Francisco Department of Public Health Primary Care Clinics (SFPCC) are included in a PrEP registry if they received a PrEP prescription, were not receiving postexposure prophylaxis, and not known to be HIV-positive.
methodsWe calculated PrEP discontinuation for patients initiating PrEP at any time from January 2012 to July 2017 and evaluated their association with demographic and risk variables using Cox regression analysis.
resultsOverall, 348 patients received PrEP over the evaluation period. The majority (84%) were men, and the cohort was racially/ethnically diverse. The median duration of PrEP use was 8.3 months. In adjusted analysis, PrEP discontinuation was lower among older patients (aHR 0.89; 95% CI 0.80-0.99; P = 0.03); but higher among black patients (compared with white patients; aHR 1.87; 95% CI 1.27-2.74; P = 0.001), patients who inject drugs (aHR 4.80; 95% CI 2.66-8.67; P < 0.001), and transgender women who have sex with men (compared with MSM; aHR 1.94; 95% CI 1.36-2.77; P < 0.001).
conclusionAge, racial/ethnic, and risk category disparities in PrEP discontinuation were identified among patients in a public health-funded primary care setting. Further efforts are needed to understand and address PrEP discontinuation among priority populations to maximize the preventive impact of PrEP, and reverse HIV-related disparities at a population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.